Melatonin Should Be Avoided in Myasthenia Gravis
You should NOT take melatonin if you have myasthenia gravis due to documented cases of disease exacerbation. Case series evidence demonstrates that melatonin can trigger worsening of myasthenia gravis symptoms within days to weeks of initiation, likely through upregulation of the adaptive immune system and potential interference with corticosteroid therapy 1.
Evidence of Harm
A case series from a tertiary referral center identified three myasthenia gravis patients who experienced clinical deterioration after starting melatonin 1. Key findings include:
- Rapid worsening occurred within days to weeks of melatonin initiation
- Stopping melatonin did not lead to immediate improvement - two patients showed no clinical recovery in the following week after discontinuation
- Standard treatments became less effective - increasing corticosteroid doses failed to produce improvement within a month, and one patient required intravenous immunoglobulins
- The mechanism appears to involve immune system upregulation and potential interaction with immunosuppressant medications
Clinical Context
While melatonin is widely used for sleep disorders and is generally well-tolerated in healthy populations 2, 3, 4, 5, myasthenia gravis represents a specific contraindication. The autoimmune nature of myasthenia gravis - involving antibodies against acetylcholine receptors, muscle-specific kinase, or lipoprotein-related protein 4 6 - makes patients particularly vulnerable to immune-modulating substances.
Alternative Approaches for Sleep Issues
If you have myasthenia gravis and insomnia, discuss these safer alternatives with your neurologist:
- Avoid medications that worsen myasthenia: β-blockers, IV magnesium, fluoroquinolones, aminoglycosides, and macrolides 7
- Consider non-pharmacologic sleep interventions first
- If medication is necessary, work with your treating neurologist to select options that don't interfere with your immunosuppressive regimen
Important Caveat
The evidence against melatonin in myasthenia gravis comes from case series rather than controlled trials, representing moderate-quality evidence. However, given the severity of myasthenia gravis exacerbations (which can lead to respiratory failure) and the availability of alternative sleep treatments, the risk-benefit ratio clearly favors avoidance 1.